Eurofins Discovery’s SafetyScreen™ and SAFETYscan® portfolios deliver comprehensive in vitro safety pharmacology screening services for early drug candidate risk assessment. Backed by decades of expertise and thousands of validated binding and functional assays, our platforms enable the detection of off-target effects and potential adverse drug reactions (ADRs) across key target classes – helping you de-risk molecules earlier and make more confident decisions toward safer preclinical drug candidates.
| Prospective Hazard Identification and Risk Assessment | ||||
|---|---|---|---|---|
| Primary Program Objective | Panel Name | Available Mode | Number of Targets | What the Panel Provides |
|
SafetyScreen44 | Binding | 44 | Industry gold-standard from 2012 recommendations* |
| SAFETYscan47 | Functional | 47 | Industry gold-standard from 2012 recommendations* | |
| SafetyScreenDelta33 | Binding / Functional | 33 | Delta panel only containing the 33 new targets to complement the 44 targets recommended in 2012**¶ | |
| SafetyScreen77 | Binding / Functional | 77 | All 77 targets defined by 2024 recommendations for broad target class and larger organ coverage** | |
| SafetyScreen18 | Binding / Functional | 18 | Designed for fast profiling, containing high-priority off-targets strongly linked to critical clinical outcomes outlined by 2024 recommendations.**¶ | |
| SafetyScreen59 | Binding / Functional | 59 | Expansion of SafetyScreen18 to cover all 77 targets highlighted in 2024 recommendations** | |
| SafetyScreen87 | Binding | 87 | Includes the SafetyScreen44 targets and expands ion channel and GPCR coverage* | |
SafetyScreen Panels are run at Poitiers (all panels) and Taipei (binding only) and SAFETYscan is run at San Diego
*Reference (Bowes et al. 2012).
**Reference (Brennan et al., Nat Rev Drug Discov, 2024).
¶ Not intended as a stand-alone IND-supporting panel
| Prospective Hazard Identification and Risk Assessment or Retrospective Assessment | ||||
|---|---|---|---|---|
| Primary Program Objective | Recommended Panel | Available Mode | Number of Targets | What the Panel Provides |
|
SAFETYscanXL | Functional/Binding | 77 | SAFETYscanXL is an expansion of SAFETYscan47 to include broader target coverage. |
| SafetyScreenPLUS | Binding | 116 | Expansion of SafetyScreen87 to cover all IQ DruSafe recommended targets. | |
| BioPrint | Binding | 135 | Broader GPCR coverage and various target class coverage. | |
| SpectrumScreen | Binding | 170 | Broadest target class coverage when thorough off-target liability examination is essential or in case of unexpected toxicity to address. | |
| Customized Panels | Binding / Functional | On demand | Tailored to your project needs | |
SAFETYscanXL is run in the USA (CA), SafetyScreenPLUS and SpectrumScreen are run in Taiwan, and BioPrint is run in France.
Target Family Distribution in Safety Profiling Assays
Our safety panels encompass critical and emerging safety targets covering a broad spectrum of clinically relevant families, predominantly GPCRs and kinases. Kinases represent an evolving safety target class recommended by the IQ DruSafe Consortium, reflecting their long-standing therapeutic relevance and documented adverse effects (Brennan, R.J. et al., Nat. Rev. Drug Discov., 2024). Please contact us for each panel composition.
Visualizing and Interpreting Safety Panel Data
Linking target activity to organ-specific adverse effects (AEs) remains a major challenge in secondary pharmacology. Eurofins Discovery is the first to introduce interactive safety panel data visualization dashboards, including In Vitro Safety Insight and SAFETYscan47 DataViz, designed to help you interact with your results, identify potential safety liabilities and inform next-step assays that will empower you to move forward with greater confidence and precision.
Specialized Panels to De-Risk Specific Safety Concerns
Follow-up with tailored panels to address specific safety concerns in your drug discovery programs. These specialized assays provide a strong mechanistic basis for weight-of-evidence safety assessments and can support regulatory submissions, including new drug applications (NDAs) and IND-filling.
| Panel Name | Background Information |
|---|---|
| Drug Abuse Potential SafetyScreen Panel | Assess the potential for drug abuse and dependency by profiling interactions with key CNS targets associated with reward, reinforcement, and addiction pathways |
| Seizure Liability SafetyScreen Panel | Support early seizure risk assessment by evaluating compound activity against targets linked to neuronal excitability and seizure susceptibility |
| Carcinogenicity Risk Assessment SafetyScreen Panel | Assess potential carcinogenic liability using a weight-of-evidence approach aligned with ICH S1B guidelines, covering nuclear hormone receptors, kinases, GPCRs, and cytokine pathways |
| Endocrine Disruption SafetyScreen Panel | Evaluate endocrine-disrupting potential by profiling interactions with key hormonal signaling targets, including nuclear hormone receptors, aromatase, thyroid peroxidase (TPO), and reductases |
| CiPA CardiacProfiler Core and Full Panels | Detect early cardiotoxicity risk while assessing well-characterized ion channels on state-of-the-art platforms (Qube384 HTS automated patch clamp) following the latest guidance for cardiac safety assessment. |
| CiPA Human iPSC-derived cardiomyocytes Multi-Electrode Array (MEA) Assays | Evaluate compound effects on electrophysiological activity of hiPSC-derived cardiomyocytes (CM) to support assessment of proarrhythmic and cardiotoxic risk |
| CiPA Human iPSC-derived cardiomyocytes FLIPR Calcium Flux SafetyScreen Assays | Assess both acute and chronic effects of compounds on Ca2+ transients in hiPSC-derived CMs, using high-throughput 384-well format to evaluate the cardiac safety of new chemical entities |
Customize Your Safety Profiling Solutions
In addition to Eurofins Discovery’s predifined safety panels, we offer customizable profiling solutions tailored to your therapeutic program. Go beyond standard panels to better align with your specific scientific objectives.
- Add targets to existing SafetyScreen panels
- Design fully customized assays to your mechanism of action
- Benefit from scientific expert guidance to interpret results and define next steps
